Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivosidenib + Nivolumab + Ipilimumab in IDH1-mutant Cholangiocarcinoma
NCT05921760Phase 2Terminated
- Sponsor
- Servier
- Start
- Oct 2023
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of ivosidenib in cholangiocarcinoma (CCA) (2 arms), sponsored by Servier. Primary endpoints: Dose Limiting Toxicities at 42 days, Adverse Events at 1 year and 2 more. Started Oct 2023; status: terminated.
02
Drugs
ivosidenib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT05921760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05921760.